Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Personal Genome Diagnostics Inc.

http://www.personalgenome.com/

Latest From Personal Genome Diagnostics Inc.

Scrip Asks...What Does 2022 Hold For Biopharma? Part 3: Technology And Science

Many industry leaders expect broad progress in the field of RNA technologies following the rapid and successful roll-out of mRNA vaccines against COVID-19 last year. Genetic medicines of various types, emerging platforms for tackling previously “undruggable” targets and the microbiome were among other areas singled out as areas to watch in 2022.

Scrip Asks Platform Technologies

Minute Insight: Quidel And Labcorp Finish Big Year For IVD Deals With Major Acquisitions

Quidel will pay $6bn for Ortho Clinical Diagnostics. Labcorp will acquire Personal Genome Diagnostics for $575m.

Minute Insights M & A

Personal Genome Diagnostics And Cleveland Diagnostics Will Use New Funding To Expand Cancer Portfolios

Personal Genome Diagnostics will use its funding to expand its liquid biopsy portfolio. Cleveland Diagnostics plans to develop early detection tests for lung and breast cancer.

Commercial Financing

Market Intel: Liquid Biopsy I – Analyzing Market Landmarks And Landmines

The worldwide liquid biopsy market is expected to reach $2.0bn by 2022, according to a new report by Meddevicetracker, "Oncology: Liquid Biopsy Products." The growth is driven by the rising global incidence of cancers, which, in turn, fuels innovation among companies to develop noninvasive diagnostic assays that obviate the need for tissue biopsy. This is the first in a two-part series providing an overview of the liquid biopsy market, as well as the technologies developed by the larger players in this space, and examining the biggest barriers and growth drivers. In the second part, we'll take a closer look at emerging companies in the sector and offer key insights from C-level attendees at the recent Liquid Biopsy Conference in San Francisco.

Cancer In Vitro Diagnostics
See All

Company Information

  • Industry
  • Biotechnology
  • Contract Research Organization-CRO
  • Services
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
      • Genomics-Proteomics
  • Other Names / Subsidiaries
    • PGDx
UsernamePublicRestriction

Register